Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by davgroon Oct 03, 2023 1:07pm
164 Views
Post# 35667226

Investors Avoiding "Risk-On" Stocks like ATE

Investors Avoiding "Risk-On" Stocks like ATERBC Capital Markets said recently that very few investors are currently looking to get aggressive in more "risk-on" stocks like clinical-stage biotech companies.  Unlike Healthcare and Pharma stocks that do well during an economic downturn these biotech companies have no revenue stream and negative cashflow.

There is definitely fear in the market and many investors are moving into cash since current yields are attractive.  Those who are thinking of adding to their ATE position or starting a new position have lots of time to make a decision before any study news is released in 2024.  Tax loss selling season is right around the corner and you could scoop up some cheap ATE shares near or at a new 52-week low.  There doesn't appear to be a rush on at the moment to buy ATE shares as evidenced by recent low daily volumes and low share price and considering no market moving news is due out until 2024..
<< Previous
Bullboard Posts
Next >>